Obesity and risk for diagnosis with prostate cancer

A new report from the International Agency Research on Cancer (IARC) Handbook Working Group has concluded that there is a definitive link between “body fatness”  and increased risk for diagnosis with 13 different types of cancer — but prostate cancer is not on that list. … READ MORE …

Of zinc ions, MRIs, and those ubiquitous research mice again

According to a story issued by the media staff for the University of Texas Southwestern Medical Center, a novel form of MRI technique may be able to distinguish between healthy prostate tissue and cancerous prostate tissue — based on zinc levels in the tissues. … READ MORE …

Pfizer to buy Medivation (developer of Xtandi)

According to news this morning, Pfizer has entered into a merger agreement which will allow the company to buy Medivation (the developer of enzalutamide, also known as Xtandi). Rumors had been rife since last Friday. … READ MORE …

The impact of the USPSTF recommendation against screening: another take

A research letter from the epidemiologists and statisticians at the American Cancer Society has just been published in JAMA Oncology. The full text of the research letter is available on line. … READ MORE …

A potential downside to metformin in the treatment of men with diabetes

There have been suggestions for some time (but no confirmation yet from large scale clinical trials) that treatment with the antidiabetic agent metformin may be beneficial in the management of at least some forms of prostate cancer. However, … READ MORE …

“Why gene tests for cancer don’t offer more answers”

An article with the above title appears to be scheduled for upcoming publication in Scientific American but is already available on line on the Scientific American web site. It may be of interest to a number of our readers. … READ MORE …

Custirsen shows no benefit in combination with cabazitaxel in mCRPC

Early this morning, OncoGenex announced the result of final analysis of data from the Phase III AFFINITY trial of custirsen + cabazitaxel + prednisone in men with metastatic, castration-resistant prostate cancer (mCRPC) who had progressed after docetaxel chemotherapy. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,453 other followers